USMV ETF Hits 52-Week High of $95.59, Last Trade at $94.40
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
- Price Fluctuation Analysis: The USMV ETF has a 52-week low of $83.99 and a high of $95.59, with the last trade at $94.40, indicating stability and potential investment appeal in the market.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average allows investors to better assess the ETF's market performance, enabling more informed investment decisions.
- Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units', allowing for flexibility in responding to market demand by creating or destroying units to accommodate investor inflows and outflows.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in ETF units focuses on significant inflows (new units created) or outflows (old units destroyed), which directly impacts the underlying holdings of the ETF and subsequently affects the market performance of its components.
Analyst Views on JNJ
Wall Street analysts forecast JNJ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for JNJ is 218.50 USD with a low forecast of 190.00 USD and a high forecast of 240.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
13 Buy
7 Hold
0 Sell
Moderate Buy
Current: 224.440
Low
190.00
Averages
218.50
High
240.00
Current: 224.440
Low
190.00
Averages
218.50
High
240.00
About JNJ
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company’s segments include Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, cardiovascular and metabolism. Its products include REMICADE (infliximab), SIMPONI (golimumab), SIMPONI ARIA (golimumab), STELARA (ustekinumab), TREMFYA (guselkumab), EDURANT (rilpivirine), and INVEGA SUSTENNA/XEPLION (paliperidone palmitate). The MedTech segment includes a portfolio of products used in cardiovascular, orthopedics, surgery, and vision categories. The Cardiovascular portfolio includes electrophysiology products to treat heart rhythm disorders and circulatory restoration products (Shockwave) for the treatment of calcified coronary artery disease (CAD) and peripheral artery disease (PAD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
